| | |
Unadjusted HR (95 % CI)
|
p-value
|
|---|
|
Sex
|
Male
|
1.46 (0.82–2.63)
|
0.20
|
|
Female
|
1
| |
|
Age
|
≥ 65 years
|
1.09 (0.62–1.90)
|
0.77
|
|
< 65 years
|
1
| |
|
Body weight change
|
Gain ≥ 5 kg
|
2.01 (1.01–3.99)
|
0.047
|
|
Others
|
1
| |
|
Location
|
Proximal
|
0.85 (0.48–1.50)
|
0.57
|
|
Distal
|
1
| |
|
Stage
|
III
|
1.32 (0.53–3.31)
|
0.55
|
|
II
|
1
| |
|
T stage
|
T 4
|
2.53 (1.36–4.72)
|
0.004
|
|
T 1–3
|
1
| |
|
N stage
|
N 2
|
2.96 (1.74–5.05)
|
<0.001
|
|
N 0–1
|
1
| |
|
Angiolymphatic invasion
|
Present
|
3.87 (2.11–7.12)
|
<0.001
|
|
Absent
|
1
| |
|
Venous invasion
|
Present
|
2.50 (1.26–4.98)
|
0.009
|
|
Absent
|
1
| |
|
Perineural invasion
|
Present
|
3.53 (2.05–6.07)
|
<0.001
|
|
Absent
|
1
| |
|
Histology
|
MAC
|
1.35 (0.42–4.34)
|
0.61
|
|
Non-MAC
|
1
| |
|
Microsatellite status
|
MSI-H
|
0.70 (0.17–2.87)
|
0.62
|
|
MSS/MSI-L
|
1
| |
- Abbreviations: HR hazard ratio, CI confidence interval, MAC mucinous adenocarcinoma, MSS microsatellite stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high
